ÂÜÀòÂÒÂ×

Llew Keltner, M.D., Ph.D., has a 40-year career in biopharma drug and business development. He is Chief Executive Officer of EPISTAT, an international healthcare technology transfer, corporate risk management and healthcare strategy company that he founded in 1972. Dr. Keltner is a founder and CEO of OncoSCAR, the company leading the field in development of diagnostics and therapeutics based on the regulatory power of transposed portions of the human retrovirome. He was the Chief Executive Officer of AgonOx, a biotech company developing OX40 agonists for use in cancer therapy, from 2011 to 2013. He was the President of Novici Biotech, a privately-held gene and protein optimization firm in 2010 and 2011. Dr. Keltner was Chief Executive Officer and President of Light Sciences Oncology, a privately-held biotechnology company developing a late stage, light-activated therapy for hepatocellular cancer, other solid tumors, and benign prostatic hypertrophy from 2001 to 2010, and again serves in that role since 2019. From 1997 to 2004, Dr. Keltner was Chief Executive Officer of Metastat, a development-stage biotech company focused on cancer metastasis.